Pharmamarketing - strategic challenges

Size: px
Start display at page:

Download "Pharmamarketing - strategic challenges"

Transcription

1 Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014

2 1. Pharmamarketing - definitions and development 2. Challenges and opportunities 3. Case study 4. Q&A

3 1. Pharmamarketing - definitions and development 2. Challenges and opportunities 3. Case study 4. Q&A

4 WHAT IS PHARMAMARKETING?

5 Definition Pharmaceutical marketing, sometimes called medico-marketing or pharma marketing in some countries, is the business of advertising or otherwise promoting the sale of pharmaceuticals or drugs.

6

7

8

9 WHEN DOES PHARMA MARKETING ENTER THE BUSINESS MODEL?

10 Pharmaceutical value chain Up to $5 billion* to develop a new medicine 10 to 15 years 19 in 20 medicines in experimental development fail, meaning a great many companies fail too 95% of the experimental medicines that are studied in humans fail to be both effective and safe * Forbes, PHARMA & HEALTHCARE 8/11/2013

11 Pharmaceutical revenue model ~20 years from application date RETURN ON INVESTMENT SALES

12 HOW MANY COMPANIES IN THE COMPETITION AND HOW MUCH CAN THEY EARN?

13 Source: Statista.com

14 Around 200 large companies competing

15 Pharma s biggest blockbusters

16 WHO REGULATES PHARMACEUTICAL MARKETING AND PROMOTION?

17 Directive 2001/83/EC Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community REGULATIONS code relating to medicinal products for human use.

18 Directive 2001/83/EC Advertising Pharmaceuticals in EU Member States must prohibit any advertising of a medicinal product for which a marketing authorisation has not been granted. The REGULATIONS advertising of a medicinal product must encourage the rational use of the product and may not be misleading.

19 US regulation Food and Drug Administration Federal Food, Drug, and Cosmetic Act Tis a set of laws passed by Congress in 1938 giving authority to the U.S. Food and Drug Administration (FDA) to oversee the safety of food, drugs, and cosmetics. This law requires that advertisements for prescription drugs be accurate and not misleading. Prescription Drug Marketing Act of 1987 An Act to amend the Federal Food, Drug, and Cosmetic Act to ban the reimportation of drugs produced in the United States, to place restrictions on the distribution of drug samples, to ban certain resales of drugs by hospitals and other health care facilities, and for other purposes

20 Professional Codes of Conduct The Pharmaceutical Research and Manufacturers of America (PhRMA) European Federation of Pharmaceutical Industries and Associations

21 HOW MUCH IS SPENT IN PROMOTION?

22 Global Promotional Spend Benchmarks $90 Billion: Total Spend of 34 Audited Countries Worldwide

23 PHARMA DETAILING

24 Pharmaceutical detailing is a 1:1 marketing technique used by pharmaceutical companies to educate a physician about a vendor's products in hopes that the physician will prescribe the company s products more often.

25 PHARMA SAMPLING

26 Pharma samples can be provided to healthcare professionals with restriction in some countries. They give immediate access to the medication and the patient can begin treatment right away.

27 MEETINGS AND SEMINARS

28 Pharmaceutical companies can invite healthcare porfessionals to attend meetings and seminars with the objective of updating/training them on their products and technologies. This can be considered as continued medical education and in some countries can give educational points.

29 KEY OPINION LEADERS ENDORSEMENT

30 Peer influence or Key Opinion Leader (KOL) endorsement is a critical success factor for pharma marketing success. KOL, or "thought leaders", are respected individuals, who influence physicians through their professional status. Pharmaceutical companies generally engage KOLs early in the drug development process to provide advocacy and key marketing feedback.

31 ADVERTISING

32 Pharmaceutical advertising aims at delivering the pharmaceutical product s sales message to physicians or direct to consumer in print, television, radio broadcast or internet.

33 CLINICAL TRIALS

34 Phase IV trial or post-marketing surveillance trial involves the safety surveillance (pharmacovigilance) and ongoing technical support of a drug after it receives permission to be sold. Phase IV studies may be required by regulatory authorities or may be undertaken by the sponsoring company for competitive (finding a new market for the drug) or other reasons (for example, the drug may not have been tested for interactions with other drugs, or on certain population groups such as pregnant women, who are unlikely to subject themselves to trials).

35 DTC DIRECT TO CONSUMERS

36 This form of advertising is directed toward patients, rather than healthcare professionals. To date only two nations permit DTC (Nation, year of legalization, link to legislation permitting DTC) New Zealand (1981) and the United States (1997). New ways to reach to the patients: via patient associations and internet.

37 EU regulation on Advertising to general public (patients) Medicinal products may be advertised to the general public if they can be/are safe to be used without the advice of a doctor or pharmacist (OTC - Over The Counter drugs) All advertising must include name of the medicinal product; necessary information for correct use of the medicinal product; specific and legible invitation to read carefully the instructions in the package leaflet. No sampling to patients! Directive 2001/83/EC

38 MAILING

39 Mailing is a way to keep in contact with customers and inform them about the pharmaceutical product development. Traditional paper mail is being replaced by e- mailing in many markets.

40 1. Pharmamarketing - definitions and historical development 2. Challenges and opportunities 3. Case study 4. Q&A

41 From last week s seminar What are the implications on pharma marketing?

42 The burden of chronic disease is soaring

43 Chronic diseases like Diabetes will see their prevalence growing everywhere and will include a large active population Social and economic value of treatments will rise accordingly Important to reach to the patient community!

44 Increasing influence of policy makers/payers on prescribing decisions

45 Increasing focus on treatment protocols to be followed by healthcare professionals E-prescribing and incentives to prescribe the recommended treatment Pharma industry to collaborate closely with policy makers and payers and support the increase in patient compliance develop the salesforce to reach to these groups

46 Need for specialised salesforce to focus on key decision makers By 2020, the role of the traditional sales representative will be largely obsolete. Conversely, the industry will have much greater need of people with the expertise to build brands; manage a network of external alliances; negotiate with governments and health insurers; liaise with secondary-care specialists; and communicate with patients.

47 Increase in pay-for-performance

48 FROM TO

49 High costs need a proof of efficacy! Biologicals to dominate the pharma market, in of 10 top-sellers expected to be large molecules! Cost of treatment per day Small molecule: US$1 Biological drug: US$22

50 Focus on best medical practice thorough pharmacoeconomic evaluations Availability of information and patient involvement in their therapies influence Pharma industry to prove that its medicine really work and this message will have to be conveyed by talented professionals and performant communication platforms

51 Increased focus on prevention rather than treatment

52 Pharma to enter the Health Management arena and change focus: from disease to prevention Patients empowered, actively working on their treatment Pharma to work on gaining patients and healthcare providers trust on their good intention

53 1. Pharmamarketing - definitions and historical development 2. Challenges and opportunities 3. Case study 4. Q&A

54 1. Pharmamarketing - definitions and historical development 2. Challenges and opportunities 3. Case study 4. Q&A

55 Sources Pharma 2020: Marketing the future - Which path will you take? PricewaterhouseCoopers, 2009 Pharma 2020: Supplying the future, PricewaterhouseCoopers, 2011 The Cost Of Creating A New Drug Now $5 Billion, Pushing Big Pharma To Change, Forbes, 2013 How Much Does Pharmaceutical Innovation Cost? A Look At 100 Companies, Forbes, 2103 THE CHANGING FACE OF THE TOP 10 PHARMACEUTICAL COMPANIES, IMS 2013 Pharmaceutical Promotional Spending: Global Trends, Cegedim, 2013 The shifting pharmaceutical industry landscape. Accounting and regulatory trends affecting reporting for 2012 and planning for 2013, Ernst&Young A wake-up call for Big Pharma, Lower profit margins suggest a need for new business models. December 2011 byvivian Hunt, Nigel Manson, and Paul Morgan, McKinsey Big pharma: Business model choices for the new market, Deloitte 2013 Global pharmaceutical industry is in a strategic crisis Business models must be adjusted, RolandBerger

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA. YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN

More information

Shifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go

Shifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Shifting Pharma Sales Models to Focus on Providing

More information

Workshop on Access to and Uptake of Biosimilar Medicinal Products

Workshop on Access to and Uptake of Biosimilar Medicinal Products EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to

More information

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation

More information

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all

More information

Strategic vision of Pharma Market

Strategic vision of Pharma Market Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected

More information

Merck s Alignment with PhRMA DTC Principles (Updated January 30, 2009)

Merck s Alignment with PhRMA DTC Principles (Updated January 30, 2009) Merck s Alignment with PhRMA DTC Principles (Updated January 30, 2009) Effective January 1, 2006, the Pharmaceutical Research Manufacturer s Association (PhRMA) implemented the PhRMA Guiding Principles

More information

Strategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002

Strategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002 Strategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002 Gill Butler has worked in the pharmaceutical industry for 21 years,

More information

Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity

Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication

More information

Promotional Tools Effect on Pharmaceuticals Marketing

Promotional Tools Effect on Pharmaceuticals Marketing Promotional Tools Effect on Pharmaceuticals Marketing Post Raj Pokharel 1* Abstract This paper shows the effect of promotional tools on pharmaceuticals marketing. The study is based on survey method using

More information

Implementation of Pharmaceutical Policy Reform. Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank

Implementation of Pharmaceutical Policy Reform. Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank Implementation of Pharmaceutical Policy Reform Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank Sector issues Critical sector for health outcomes Characterized by market

More information

New Indications & Cross- Label Dispensing

New Indications & Cross- Label Dispensing New Indications & Cross- Label Dispensing Date: 11/11/2015 Position Paper Executive Summary Innovation is a continuous process, and appropriate incentives are needed to encourage development of the full

More information

Statement on Drug Pricing in America: A Prescription for Change. Submitted to the Senate Finance Committee

Statement on Drug Pricing in America: A Prescription for Change. Submitted to the Senate Finance Committee Statement on Drug Pricing in America: A Prescription for Change Submitted to the Senate Finance Committee January 29, 2019 America s Health Insurance Plans (AHIP) is the national association whose members

More information

LAUNCH MANAGEMENT. Preparing for a Global Launch. Through Alignment, Communication, Collaboration and Transparency

LAUNCH MANAGEMENT. Preparing for a Global Launch. Through Alignment, Communication, Collaboration and Transparency LAUNCH MANAGEMENT Preparing for a Global Launch Through Alignment, Communication, Collaboration and Transparency Presented by: Lori Peters, QPharma, SVP Commercial Operations Ted Hoffman, Centerline Consulting,

More information

Report of the Signatory Companies: Volume XII

Report of the Signatory Companies: Volume XII 2016 Introduction The Pharmaceutical Research and Manufacturers of America s (PhRMA) Guiding Principles on Direct-to-Consumer (DTC) Advertisements about Prescription Medicines ( PhRMA Guiding Principles

More information

D&E DATOS Y ESTRATEGIAS PHYSICIANS PERCEPTIONS ABOUT THE PROMOTIONAL PRESSURE BY NATIONAL AND MULTINATIONAL PHARMACEUTICAL COMPANIES

D&E DATOS Y ESTRATEGIAS PHYSICIANS PERCEPTIONS ABOUT THE PROMOTIONAL PRESSURE BY NATIONAL AND MULTINATIONAL PHARMACEUTICAL COMPANIES PHYSICIANS PERCEPTIONS ABOUT THE PROMOTIONAL PRESSURE BY NATIONAL AND MULTINATIONAL PHARMACEUTICAL COMPANIES FOR THE PERIOD 2005-2013 Survey 2013 1 CURRENT SCENARIO IN ARGENTINA The pharmaceutical industry

More information

Innovative Approaches to Saving Patients Money on Prescription Drug Costs

Innovative Approaches to Saving Patients Money on Prescription Drug Costs Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices

More information

Legislative and Regulatory Modernization for Therapeutic Products

Legislative and Regulatory Modernization for Therapeutic Products Legislative and Regulatory Modernization for Therapeutic Products Maurica Maher Associate Director, Office of Legislative and Regulatory Modernization, Health Products and Food Branch, Health Canada Presented

More information

Innovations in Drug Pricing and Reimbursement:

Innovations in Drug Pricing and Reimbursement: ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report and Reimbursement Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports

More information

EPSA EC CONSULTATION:

EPSA EC CONSULTATION: EPSA EC CONSULTATION: STRATEGY TO BETTER PROTECT PUBLIC HEALTH BY STRENGTHENING AND RATIONALISING EU PHARMACOVIGILANCE: PUBLIC CONSULTATION ON LEGISLATIVE PROPOSALS 1 Executive Summary: The European Pharmaceutical

More information

Ashfield Commercial. Commercial & Medical Services. INSIGHT & PERFORMANCE Business Edge InforMed Insight Pharma Marketing Academy

Ashfield Commercial. Commercial & Medical Services. INSIGHT & PERFORMANCE Business Edge InforMed Insight Pharma Marketing Academy COMMERCIAL Ashfield In2Focus Pharmexx Ashfield Commercial Ashfield Healthcare Ireland Ashfield KK Expansis Ashfield MCG CLINICAL Ashfield In2Focus Pharmexx Ashfield Healthcare Ashfield Healthcare Ireland

More information

Commission's proposal to review EU pharmaceutical legislation

Commission's proposal to review EU pharmaceutical legislation SPEECH/01/354 Mr Erkki Liikanen Member of the European Commission, responsible for Enterprise and the Information Society Commission's proposal to review EU pharmaceutical legislation Press conference

More information

The Move Toward Patient Centricity. LIFE SCIENCES Patient Connect Accelerator ebook

The Move Toward Patient Centricity. LIFE SCIENCES Patient Connect Accelerator ebook The Move Toward Patient Centricity LIFE SCIENCES Patient Connect Accelerator ebook are in a unique position to drive value and they must to successfully compete with new competitors (e.g. large consumer

More information

BULGARIAN PHARMACEUTICAL POLICY AND LEGISLATION IN THE CONTEXT OF THE EU ACCESSION

BULGARIAN PHARMACEUTICAL POLICY AND LEGISLATION IN THE CONTEXT OF THE EU ACCESSION BULGARIAN PHARMACEUTICAL POLICY AND LEGISLATION IN THE CONTEXT OF THE EU ACCESSION DR SVETLANA SPASSOVA DIRECTOR NATIONAL HEALTH POLICY MINISTRY OF HEALTH European Health Conference 29th September 2006

More information

Hospira at a 5/20/2015. The World s Leading Provider of Injectable Drugs and Infusion Technologies

Hospira at a 5/20/2015. The World s Leading Provider of Injectable Drugs and Infusion Technologies Sumant Ramachandra, MD, PhD SVP and Chief Scientific Officer Alliance for Health Reform May 20 th, 2015 Hospira at a glance The World s Leading Provider of Injectable Drugs and Infusion Technologies Market

More information

THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS

THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,

More information

WHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs

WHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs 1 Executive Summary In today s complex healthcare landscape, the success or failure of a new therapeutic intervention depends

More information

Doctor/pharma relationships: the latest research

Doctor/pharma relationships: the latest research Creating connections, improving healthcare Doctor/pharma relationships: the latest research medicine media metamorphosis The huge shift in knowledge sharing has affected how doctors interact with the healthcare

More information

Pharmaceuticals in a Global Environment

Pharmaceuticals in a Global Environment Pharmaceuticals in a Global Environment The Story of Heartburn Anne Johnson, M.D. 100 University Dr. Long Beach, CA 90840 Lic No: 1234 DEA #: 98765 The Purple Pill Prilosec, 20 mg As needed for acid reflux

More information

Policy principles for a competitive healthcare environment

Policy principles for a competitive healthcare environment Policy principles for a competitive healthcare environment Pharmaceutical Research and Development Industry Malta Association (PRIMA) PRIMA is an affiliate of the European Federation of Pharmaceutical

More information

Developing Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy

Developing Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What

More information

Policies Approved by the 2018 ASHP House of Delegates

Policies Approved by the 2018 ASHP House of Delegates House of Delegates Policies Approved by the 2018 ASHP House of Delegates 1801 Unit Dose Packaging Availability To advocate that pharmaceutical manufacturers provide all medications used in health systems

More information

Orphan Medicinal Products

Orphan Medicinal Products Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000

More information

FOCUS REIMBURSEMENT STRATEGY TO DEMONSTRATE FULL VALUE STORY

FOCUS REIMBURSEMENT STRATEGY TO DEMONSTRATE FULL VALUE STORY WHITE PAPER FOCUS REIMBURSEMENT STRATEGY TO DEMONSTRATE FULL VALUE STORY By Nicole May, Research Analyst at Cutting Edge Information OVERVIEW National and private payers, especially in the US and EU, are

More information

'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push

'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push Other Publications: Scrip Medtech Insight In Vivo Rose Sheet This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers,

More information

HORIZON 2030 Executive Summary LPIA Workshop

HORIZON 2030 Executive Summary LPIA Workshop HORIZON 2030 Executive Summary LPIA Workshop 30th September 2017 1 CONTENTS P 4 1.0 Introduction 1.1 The Event & Objectives 1.2 The Agenda & Presentations 1.3 The Attendance 2.0 The profession 2.1 Role

More information

POLICY POSITION ON NAMING OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS. October 31, 2006

POLICY POSITION ON NAMING OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS. October 31, 2006 POLICY POSITION ON NAMING OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS October 31, 2006 POLICY POSITION ON NAMING OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS 1 This is a joint position statement of

More information

CURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE. The role of Biosimilar Medicines

CURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE. The role of Biosimilar Medicines CURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE The role of Biosimilar Medicines Marc A. Mahl, MD MBA(INSEAD) President, Medicines for Europe Baltimore, 05 th September 2018 patients quality

More information

Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers

Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Association for Accessible Medicines Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Key Takeaways Generic drugs play an important role in the U.S. health care system,

More information

6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels

6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels www.eurordis.org 6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels Brussels, 24-25 May 2012 www.eurordis.org THE NEW PARADIGMS OF RARE DISEASES TREATMENT DEVELOPMENT & ACCESS

More information

Jordi Aparici Market Intelligence Consultant

Jordi Aparici Market Intelligence Consultant Jordi Aparici Market Intelligence Consultant Helping pharma companies make robust decisions based on market, competitors and patient knowledge Market Intelligence Strategy Marketing Market Research Data

More information

Prescription Medicines: Costs in Context

Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical

More information

Supporting Innovation through Scientific Advice

Supporting Innovation through Scientific Advice Supporting Innovation through Scientific Advice PEARRL Regulatory Science Symposium, 21 st June 2017, University College Cork HPRA Dr Peter Kiely Disclaimer All views expressed in this presentation are

More information

2 Pharmacovigilance. 2.1 Fundamentals of Pharmacovigilance

2 Pharmacovigilance. 2.1 Fundamentals of Pharmacovigilance Pharmacovigilance 2 Pharmacovigilance 2 In this chapter, the fundamentals of pharmacovigilance are outlined with a particular emphasis on the role of healthcare professionals in reporting adverse drug

More information

Biopharma in the coming era of connected health

Biopharma in the coming era of connected health 14 Health-care focus: Perspective Celia Johnson Biopharma in the coming era of connected health Disruptive technologies are already reshaping the industry. Here s how executives can meet the resulting

More information

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact. Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget

More information

March 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette:

March 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette: March 2, 2015 The Honorable Fred Upton Chairman Energy and Commerce Committee House of Representatives Washington, DC 20515 The Honorable Frank Pallone Ranking Member Energy and Commerce Committee House

More information

This video gives an overview of the centralised procedure at the European Medicines Agency

This video gives an overview of the centralised procedure at the European Medicines Agency This video gives an overview of the centralised procedure at the European Medicines Agency In Europe today, all medicines must have a marketing authorisation before they can be used by patients And there

More information

Importance of Pharmacovigilance for Pharmaceutical Industry

Importance of Pharmacovigilance for Pharmaceutical Industry Importance of Pharmacovigilance for Pharmaceutical Industry JARIR AT THOBARI, MD, DPHARM, PHD FACULTY OF MEDICINE GADJAH MADA UNIVERSITY YOGYAKARTA, INDONESIA Role of Pharma Company Globally Investment

More information

Prescription Medicines: Costs in Context

Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical

More information

I D C T E C H N O L O G Y S P O T L I G H T

I D C T E C H N O L O G Y S P O T L I G H T I D C T E C H N O L O G Y S P O T L I G H T C o n f r o n t i n g C h r onic Disease at the Point of M a x i m u m I mpact January 2017 Adapted from Business Strategy: Demand for IT Services Related to

More information

Investigational Medicinal Product (IMP) Management Standard Operating Procedure

Investigational Medicinal Product (IMP) Management Standard Operating Procedure Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support

More information

ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014

ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014 ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014 Health care is in the middle of a perfect storm Changing demographics Unmet needs

More information

BGMA Associate Membership

BGMA Associate Membership BGMA Associate Membership Making medicines affordable Promoting Innovation November 2011 GENERICS -THE FACTS Generic medicines meet the same standards of quality, safety and efficacy as originator brands.

More information

Indian Pharmaceutical Industry. January 2018

Indian Pharmaceutical Industry. January 2018 Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400

More information

Overview of the Agency s role, activities and priorities for An agency of the European Union

Overview of the Agency s role, activities and priorities for An agency of the European Union Overview of the Agency s role, activities and priorities for 2015 An agency of the European Union The Agency's prioroties for 2015 In light of the above influences and other business-environment factors,

More information

HCP ENGAGEMENT REPORT: HOW TO MAXIMIZE MARKETING ROI

HCP ENGAGEMENT REPORT: HOW TO MAXIMIZE MARKETING ROI HCP ENGAGEMENT REPORT: HOW TO MAXIMIZE MARKETING ROI HCP ENGAGEMENT REPORT: HOW TO MAXIMIZE MARKETING ROI Digital technology is changing healthcare fast, opening a new, digital world for pharma marketers

More information

First Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD

First Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA

More information

Regulatory Market Update: What are the major changes and differences worldwide?

Regulatory Market Update: What are the major changes and differences worldwide? Regulatory Market Update: What are the major changes and differences worldwide? Marlene E. Haffner MD, MPH, CEO Haffner Associates Orphan Drug Summit 2015 Copenhagen, Denmark September 17, 2015 Orphan

More information

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the

More information

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics

More information

Assuring Integrity while Facilitating Innovation in Medical Research

Assuring Integrity while Facilitating Innovation in Medical Research Assuring Integrity while Facilitating Innovation in Medical Research IMPACT OF CONFLICT OF INTEREST POLICIES ON INNOVATION June 5, 2013 IOM Proposed Questions What is the industry perspective on the impact

More information

How to Ensure Patient-Centred Pharmacare is Cost-Effective Healthcare A Consultation on Patented Medicine Prices Review Board & Biologic Medicines

How to Ensure Patient-Centred Pharmacare is Cost-Effective Healthcare A Consultation on Patented Medicine Prices Review Board & Biologic Medicines JANUARY 31, 2018 8:30 am 4:00 pm MARRIOTT TORONTO DOWNTOWN EATON CENTRE HOTEL Toronto, Ontario Forum #1: A Case for Prescription Medicines As Essential Healthcare Services It is no longer feasible to consider

More information

Clinical Supply Packaging for Biological Products

Clinical Supply Packaging for Biological Products Clinical Supply Packaging for Biological Products Part 2 of the Clinical Supply Knowledge Share Series: Understanding and Delivering your Global Clinical Supply Chain Almac Clinical Services Clinical Supply

More information

Romania. Raluca Vasilescu Cabinet M Oproiu. Pharmaceutical Trademarks 2015/2016. A Global Guide

Romania. Raluca Vasilescu Cabinet M Oproiu. Pharmaceutical Trademarks 2015/2016. A Global Guide Romania Raluca Vasilescu Cabinet M Oproiu Pharmaceutical Trademarks 2015/2016 A Global Guide Romania Cabinet M Oproiu Author Raluca Vasilescu Selection, clearance and registration In Romania, pharmaceutical

More information

@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015

@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015 How to Win Physician Collaboration Models for Advancing Access to Lifesaving Therapies @ALSETF #EAP2015 Jess B. Rabourn CBI Expanded Access Conference July 22, 2015 How to Win Now that we want Expanded

More information

Roche Position 1 on Similar Biotherapeutic Products Biosimilars

Roche Position 1 on Similar Biotherapeutic Products Biosimilars Roche Position 1 on Similar Biotherapeutic Products Biosimilars Similar Biotherapeutic Products Biosimilars Innovative biotherapeutic products (e.g.monoclonal antibodies) are losing market exclusivity,

More information

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach CADTH Symposium April 6, 2009 Maurica Maher, MD, MSc Associate Director Office of Legislative

More information

The Finnish Medicines Agency Fimea is in charge of regulating and developing the pharmaceutical sector to promote the health of Finland s population.

The Finnish Medicines Agency Fimea is in charge of regulating and developing the pharmaceutical sector to promote the health of Finland s population. 1 (11) FIMEA S STRATEGY 2011 2020 Mission The Finnish Medicines Agency Fimea is in charge of regulating and developing the pharmaceutical sector to promote the health of Finland s population. Fimea s tasks

More information

FIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution

FIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution Purpose: The purpose of this document is to provide a set of recommendations on therapeutic interchange

More information

Key Activities. Ofer Reizes, Ph.D. Skills Development Director

Key Activities. Ofer Reizes, Ph.D. Skills Development Director Key Activities Ofer Reizes, Ph.D. Skills Development Director 1 Key Activities Core Question: What key activities required for your Value Propositions? Key Partners Key Activities Key Resources Value Proposition

More information

Update on Real World Evidence Data Collection

Update on Real World Evidence Data Collection Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large

More information

Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework

Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework Table of Contents Preamble... 3 Background... 3 What is a rare disease?... 3 What is an orphan drug?... 3 Unique Challenges

More information

Huntsworth Plc. Capital Markets Day

Huntsworth Plc. Capital Markets Day Huntsworth Plc Capital Markets Day 1 Agenda 1:45 Intro Paul Taaffe / Neil Jones 2:05 apothecom - An introduction to medical affairs 2:30 TCEG The changing nature of engagement 2:55 Refreshments 3:25 Evoke

More information

Healthcare Marketing.» Service Line Strategies & Beyond

Healthcare Marketing.» Service Line Strategies & Beyond Healthcare Marketing Service Line Strategies & Beyond Table of Contents Current State of Healthcare Marketing...3 Marketing Initiatives... 4 Marketing Center of Excellence...7 Getting Started...9 Digital

More information

Teva operates in both the generics and branded medicines markets, with generics being our primary area of focus.

Teva operates in both the generics and branded medicines markets, with generics being our primary area of focus. Opening statement by Ms Sandra Gannon, General Manager, Teva Pharmaceuticals Ireland, to the Oireachtas Joint Committee on Health and Children, Thursday 5 March 2015 Good morning. Chairman, Committee and

More information

Prescription Medicines: Costs in Context

Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical

More information

Biopharmaceutical Company Communications with Health Care Stakeholders RESULTS OF SURVEYS WITH PAYERS AND PROVIDERS

Biopharmaceutical Company Communications with Health Care Stakeholders RESULTS OF SURVEYS WITH PAYERS AND PROVIDERS Biopharmaceutical Company Communications with Health Care Stakeholders RESULTS OF SURVEYS WITH PAYERS AND PROVIDERS DECEMBER 2017 Executive Summary As biomedical research continues to push into new frontiers

More information

Beyond Real World Evidence

Beyond Real World Evidence Beyond Real World Evidence How to improve utilisation of Real World Data throughout an organisation Real World Evidence (RWE) has demonstrated real business value by enabling medical researchers to analyse

More information

Talking to Active Investigators: Interview Findings

Talking to Active Investigators: Interview Findings April 5, 2017 Talking to Active Investigators: Interview Findings Terri Hinkley RN, BScN, MBA, CCRC Association for Clinical Research Professionals (ACRP) Active Investigator Interviews Active Investigator:

More information

New Complexities in Pricing Orphan and Ultra-Orphan Drugs

New Complexities in Pricing Orphan and Ultra-Orphan Drugs New Complexities in Pricing Orphan and Ultra-Orphan Drugs September 28, 2010 Agenda Orphan drugs and their prices are less rare Changes in ultra-orphan markets Increased competition Big pharma enters When

More information

American Heart Association/American Stroke Association Statement on Drug Formularies

American Heart Association/American Stroke Association Statement on Drug Formularies American Heart Association/American Stroke Association Statement on Drug Formularies Underlined terms are defined on page 4 of the document. 1. The AHA supports a formulary system that: Assures access

More information

Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options

Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options Ashoke Bhattacharjya, PhD Robert E Campbell Pharmaceutical Seminar Rutgers Business School Feb 15, 2017 1

More information

News For Immediate Release

News For Immediate Release News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly

More information

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT

More information

Drugs, medical progress,

Drugs, medical progress, Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions

More information

SWOG

SWOG SWOG http://swog.org Page 1 of 5 pages Original Release Date: May 2007 Departments Affected: All Revision Date: May 2014 POLICY ON ADVERTISING FOR SUBJECT RECRUITMENT AND TRIAL PROMOTION When Federal human

More information

Rating Methodology by Sector. Pharmaceuticals

Rating Methodology by Sector. Pharmaceuticals Last Updated: December 7, 2011 Rating Methodology by Sector Pharmaceuticals Pharmaceuticals are mainly categorized into ethical drugs, which are provided to patients by hospital pharmacies or by dispensing

More information

Gallagher Healthcare Practice

Gallagher Healthcare Practice Gallagher Healthcare Practice Keeping Your Organization in Good Health As the healthcare industry transitions from volume to value, you need a partner with access to a wide set of solutions that can be

More information

Market Analysis & Segmentation Bioshares Biotech Summit July Duncan Ross Managing Director & CEO

Market Analysis & Segmentation Bioshares Biotech Summit July Duncan Ross Managing Director & CEO Market Analysis & Segmentation Bioshares Biotech Summit July 2016 Duncan Ross Managing Director & CEO 1 Disclaimer This presentation has been prepared by AtCor Medical Holdings Limited (AtCor or the Company)solely

More information

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS How TOPRA can support you as you drive your regulatory career forward ABOUT TOPRA TOPRA (The Organisation for Professionals in Regulatory Affairs)

More information

Pharmaceutical pricing, i reimbursement, Europe: an overview (I) Elias Mossialos and Reinhard Busse

Pharmaceutical pricing, i reimbursement, Europe: an overview (I) Elias Mossialos and Reinhard Busse Pharmaceutical pricing, i reimbursement, HTA and cost containment measures in Europe: an overview (I) Elias Mossialos and Reinhard Busse Policy issues in pharmaceutical markets Structure of the pharmaceutical

More information

PhRMA GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES

PhRMA GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES PhRMA GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES P hrma GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES PREAMBLE Given the progress

More information

Primer: The Biotechnology Industry Han Zhong l September 2011

Primer: The Biotechnology Industry Han Zhong l September 2011 Primer: The Biotechnology Industry Han Zhong l September 2011 Introduction The budding biotechnology industry covers a wide range of human health biologic products and technologies that are created by

More information

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements. H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO

More information

Enterprise Performance Management in the Pharmaceutical Industry. kpmg.co.uk

Enterprise Performance Management in the Pharmaceutical Industry. kpmg.co.uk Enterprise Performance Management in the Pharmaceutical Industry kpmg.co.uk Are your performance management processes, metrics and tools prepared for tomorrow s strategic challenges in pharmaceuticals?

More information

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Adis Journals and Newsletters The premier collection of drug-focused medical journals adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,

More information

Covering a medical advisory board meeting and creating the report or publication: The role- of the professional medical writer

Covering a medical advisory board meeting and creating the report or publication: The role- of the professional medical writer Covering a medical advisory board meeting and creating the report or publication: The role- of the professional medical writer Namrata Singh and Ritu Sharma Turacoz Healthcare Solutions, New Delhi, India

More information

Summary of the Actions of the ASHP House of Delegates. June 3 and 5, 2018

Summary of the Actions of the ASHP House of Delegates. June 3 and 5, 2018 Summary of the Actions of the ASHP House of Delegates June 3 and 5, 2018 The House of Delegates Ultimate authority over ASHP professional policies One annual session consisting of 4 meetings: 2 meetings

More information

Rx EDGE. Retail strategy considerations for the launch of a new product or indication. White Paper. Pharmacy Networks

Rx EDGE. Retail strategy considerations for the launch of a new product or indication. White Paper. Pharmacy Networks Retail strategy considerations for the launch of a new product or indication White Paper Introduction One of the most difficult and stressful marketing decisions in pharmaceutical new product launches

More information